February 15, 2024
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
January 03, 2024
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorpha...
December 14, 2023
Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk
More than 200 Alkermes employees recently took time out of their normal work day to contribute their time and talents to a variety of local Massachusetts nonprofit organizations as part of our fifteenth Alkermes in Action employee volunteer day.
Now in its seventh year, we are proud of the impact the Alkermes Inspiration Grants® program has made in support of creative and innovative programs designed to make a difference for patient communities. Visit the program page to learn about the latest group of grant recipients.
Alkermes employees work with urgency -- in the laboratory, in the clinic and in the community -- seeking to make a meaningful difference for people living with complex and difficult-to-treat diseases. For many of our employees, this work is part of their personal mission to help patients, families and communities.
Olanzapine and samidorphan - Schizophrenia or Bipolar I Disorder (pediatric)
ALKS 2680 - Narcolepsy
Orexin Agonists - Non-Orphan Indications